U.S. Markets close in 4 hrs 40 mins

Medigene AG (MDGEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
5.860.00 (0.00%)
As of 12:12PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.86
Open5.86
Bid0.00 x 0
Ask0.00 x 0
Day's Range5.86 - 5.86
52 Week Range3.80 - 6.68
Volume22,804
Avg. Volume1,107
Market Cap144.302M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.76
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event
    GlobeNewswire

    Medigene to Take Part in Cell Therapy Panel at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

    MARTINSRIED, Germany and MUNICH, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announced today that Prof. Dr. Dolores J. Schendel, Chief Executive Officer and Chief Scientific Officer of Medigene, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, on Wednesday, 6 January 2021 from 8:00 am EST. The panel, entitled “Challenges and Opportunities in Cell Therapy”, will explore the potential of next generations of cell therapy to respond to current hurdles and challenges and how these will be positioned in the current treatment paradigm. Investors can pre-register for the panel discussion here.About MedigeneMedigene AG (FSE: MDG1, Prime Standard, ISIN DE000A1X3W00) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.For more information, please visit www.medigene.comThis press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.Medigene Dr. Gary Waanders, Dr. Anna Niedl Phone: +49 89 2000 3333 01 e-mail: investor@medigene.comLifeSci Advisors Mary-Ann Chang Phone: +44 7483 284 853 e-mail: mchang@lifesciadvisors.comIn case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

  • GlobeNewswire

    Medigene enters Phase I clinical development with its TCR-T immunotherapy MDG1021 in hematological cancers

    Medigene AG (FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, has received approval from the Dutch regulatory authority (the Central Committee on Research Involving Human Subjects, CCMO) to begin a first clinical trial of MDG1021. MDG1021, which targets the antigen HA-1, thus becomes Medigene’s second proprietary T cell receptor-modified T cell (TCR-T) immunotherapy candidate to enter clinical development.

  • GlobeNewswire

    Medigene’s PD1-41BB Switch Receptor Enhances TCR-T Cell Activity Towards Solid Tumors

    MARTINSRIED, Germany and MUNICH, Germany, June 22, 2020 -- Medigene AG (Medigene, FSE: MDG1), a clinical stage immuno-oncology company focusing on the development of T cell.